金融界消息 截至2025年8月19日收盘，苑东生物（688513）报收于65.02元，上涨3.93%，换手率 3.92%，成交量6.92万手，成交金额4.46亿元。 通过天眼查大数据分析，成都苑东生物制药股份有限公司共对外投资了12家企业，参与招投标项目3437 次，知识产权方面有商标信息355条，专利信息183条，此外企业还拥有行政许可239个。 资金流向方面，今日主力资金净流入7677.59万元，占比成交额17.21%。其中，超大单净流入3711.68万 元、占成交额8.32%，大单净流入3965.92万元、占成交额8.89%，中单净流出流入747.76万元、占成交 额1.68%，小单净流出8425.35万元、占成交额18.88%。 来源：金融界 苑东生物最新一期业绩显示，截至2025中报，公司营业总收入6.54亿元、同比减少2.25%，归属净利润 1.37亿元，同比减少6.77%，扣非净利润1.04亿元，同比减少8.68%，流动比率3.463、速动比率3.091、 资产负债率19.71%。 天眼查商业履历信息显示，成都苑东生物制药股份有限公司，成立于2009年，位于成都市，是一家以从 事医药制造业为主的 ...

财报季，社保基金持股动向曝光！二季度末社保基金共现身12只个股前十大流通股东榜，新进2只，增 持6只。 证券时报·数据宝统计显示，社保基金最新出现在12只科创板股前十大流通股东名单中，合计持股量 4942.64万股，期末持股市值合计24.11亿元。持股变动显示，新进2只，增持6只，减持3只，1只股持股 量保持不变。 社保基金持有科创板股中，从前十大流通股东名单中社保基金家数来看，南微医学、凯立新材等2只股 有3家社保基金集中现身，持股量分别为917.85万股、636.42万股。 市场表现方面，获社保基金持有的科创板股7月以来平均上涨29.42%。从具体个股看，鼎通科技累计涨 幅92.20%，表现最好，苑东生物、南微医学等分别上涨52.36%、41.13%位居其后。从具体个股看，鼎 通科技累计涨幅92.20%，表现最好，苑东生物、南微医学等分别上涨52.36%、41.13%位居其后。（数 据宝） | 代码 | 简称 | 社保基金家 | | 社保基金持股量（万 | 环比 | 占流通股比例 | 持股市值（万 | | --- | --- | --- | --- | --- | --- | --- | --- | | ...

证券日报网讯 8月18日晚间，苑东生物发布公告称，公司第四届董事会第七次会议审议通过了《关于的 议案》等多项议案。 （文章来源：证券日报） ...

证券日报网讯 8月18日晚间，苑东生物发布公告称，公司第四届监事会第六次会议审议通过了《关于的 议案》等多项议案。 （文章来源：证券日报） ...

智通财经APP讯，苑东生物(688513.SH)发布2025年半年度报告，该公司营业收入为6.54亿元，同比减少 2.25%。归属于上市公司股东的净利润为1.37亿元，同比减少6.77%。归属于上市公司股东的扣除非经常 性损益的净利润为1.04亿元，同比减少8.68%。基本每股收益为0.77元。营业收入及净利润较上年同期 下降，主要系执行第十批国家集中带量采购导致化学制剂销售收入下降及报告期内股权激励费用同比增 加所致。 ...

Core Viewpoint - Chengdu Yuandong Biopharmaceutical Co., Ltd. has signed an agreement with an affiliated party to procure a production information system, aiming to enhance digital and intelligent management in the pharmaceutical industry [1][3]. Summary by Sections 1. Overview of the Related Transaction - The company’s wholly-owned subsidiary, Chengdu Shod Pharmaceutical Co., Ltd., plans to purchase a production information system from Beijing Qilijia Technology Co., Ltd. for a total amount of 2.2 million RMB, with a contract duration of three years [1][3][7]. 2. Basic Information of the Related Party - Beijing Qilijia Technology Co., Ltd. has a registered capital of 5 million RMB and was established on October 25, 2002. The company specializes in software development, technology consulting, and related services [2][5]. 3. Financial Data of the Related Party - As of June 30, 2025, Qilijia reported total assets of 1470.98 million RMB and total liabilities of 205.94 million RMB, with an owner's equity of 1265.04 million RMB. The company had a revenue of 392.14 million RMB in the first half of 2025 [5]. 4. Necessity and Impact of the Related Transaction - The transaction is essential for the company to implement digital and intelligent management in pharmaceutical production, aligning with the interests of the company and all shareholders. The pricing of the transaction is fair and does not harm the interests of minority shareholders [9][11]. 5. Approval Process for the Related Transaction - The independent directors and the board of supervisors have approved the transaction, confirming that it complies with the company's procurement management system and is based on fair market conditions [10][11].

经全体与会独立董事审议：本次关联交易是基于公司实施生产数字化智能管 理的实际业务而产生，主要目的是为了加快推进数字化、智能化在制药产业中融 合，实现药品生产数字化智能管理，符合公司和全体股东的利益，具有必要性。 本次交易严格按照公司采购管理制度及采购招标流程遴选供应商，按照公平、公 开、公正的原则从服务能力、解决方案、项目实施经验、项目团队能力等方面进 行综合全面考察，通过招投标流程比价，在符合商业惯例的前提下，从交易价格 谈判、付款方式及验收标准等方面保证上市公司利益，不会损害公司及股东特别 是中小股东的利益。我们同意将该关联交易事项提交公司第四届董事会第七次会 议审议，届时关联董事将回避表决。 表决结果：3 票同意、0 票反对、0 票弃权。 独立董事：李卫锋、程增江、方芳 成都苑东生物制药股份有限公司 第四届独立董事专门会议第三次会议决议 成都苑东生物制药股份有限公司（以下称"公司"）第四届独立董事专门会议 第三次会议通知于 2025 年 8 月 7 日以电话/微信等方式临时向全体独立董事发出， 会议于 2025 年 8 月 8 日以通讯表决方式召开。本次会议应出席独立董事 3 名， 实际出席独立董事 3 ...

Core Viewpoint - The company has decided to extend the investment timeline for certain fundraising projects, specifically the "Drug Clinical Research Project," to align with actual progress and strategic goals, without altering the project's content or financial commitments [3][6][8]. Fundraising Overview - The company raised a total of RMB 1,334,792,400.00 through the issuance of 30,090,000 shares at RMB 44.36 per share, with a net amount of RMB 1,222,708,416.51 after deducting issuance costs [1][2]. - The funds are stored in a dedicated account, and a regulatory agreement is in place with the sponsor and the bank [1]. Investment Project Details - The company has made adjustments to its fundraising project allocations, including a change in the use of RMB 61 million from the "Marketing Network Construction Project" to fund a new project for its subsidiary [2]. - The total investment for the new project is RMB 10,905 million, with RMB 6,100 million sourced from the adjusted funds [2]. Project Timeline Adjustments - The investment period for the "Drug Clinical Research Project" has been extended by two years, now set to conclude on August 31, 2027 [6][8]. - The project includes two sub-projects: the "Vildagliptin Tablets" and "Morphine Sulfate and Naloxone Controlled-Release Capsules," with the former having completed Phase III trials [6]. Reasons for Delay - The delay is attributed to the need for additional clinical trials for the "Vildagliptin Tablets" to meet submission requirements for market approval, considering competitive market conditions and commercialization risks [6][8]. Impact of Delay - The project delay is deemed a prudent decision that will not adversely affect the company's normal operations or alter the investment's total amount, purpose, or scale [8][9]. Approval Process - The board and supervisory committee have approved the project delays, confirming that no shareholder meeting is required for this decision [8][9]. - Both the board and supervisory committee emphasize that the delay is in the best interest of shareholders and aligns with the company's long-term sustainable development [9]. Sponsor's Review - The sponsor has reviewed the project delay and found that all necessary approval procedures have been followed, with no changes to the project's financial commitments or objectives [9].

Core Viewpoint - Yuan Dong Bio (688513.SH) reported a decline in both revenue and net profit for the first half of 2025, primarily due to the implementation of the tenth batch of national centralized procurement and increased stock incentive expenses [1] Financial Performance - The company achieved operating revenue of 654 million yuan, a year-on-year decrease of 2.25% [1] - Net profit attributable to shareholders was 137 million yuan, down 6.77% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 104 million yuan, reflecting an 8.68% year-on-year decline [1] - Basic earnings per share stood at 0.77 yuan [1]

人民财讯8月18日电，苑东生物(688513)8月18日晚间披露2025年半年报，公司上半年实现营业收入6.54 亿元，同比下降2.25%；归母净利润1.37亿元，同比下降6.77%。基本每股收益0.77元。报告期内，营业 收入及净利润较上年同期下降，主要系执行第十批国家集中带量采购导致化学制剂销售收入下降及报告 期内股权激励费用同比增加所致。 ...